Costs associated with R&D
|
Base-case
|
$4,461,200,000 [17] |
€3,795,249,282 |
€3,165,890,999 |
Scenario 1 Cost R&D (CI)
|
$3,114,000,000 [17] |
€2,649,154,098 |
€2,209,850,393 |
Scenario 2 Cost R&D (CI)
|
$6,001,300,000 [17] |
€5,105,449,097 |
€4,258,823,109 |
Scenario 3 Cost R&D (uncapitalized)
|
$1,032,000,000 [17] |
€877,947,023 |
€732,358,897 |
Cost associated with each new indication
|
Base-case
|
$300,000,000 [18] |
€267,020,244 |
€222,740,834 |
Scenario 4 based on AIM method
|
$446,120,000 [33] |
€379,524,928 |
€316,589,100 |
Cost of product manufacturing (per gram)
|
Base-case
|
$51 [24] |
€42.61 |
€35.55 |
Scenario 5 cost manufacturing (low)
|
$26 [25] |
€25.89 |
€21.59 |
Scenario 6 cost manufacturing (high)
|
$134 [25] |
€133.43 |
€111.30 |
Profit margin in %
|
Base-case
|
20 [9] |
20 |
20 |
Scenario 7 profit margin 0%
|
0 |
0 |
0 |
Scenario 8 highest profit margin
|
76.5 [34] |
76.5 |
76.5 |
Patent period
|
Scenario 9 patent period
|
2035 & 2036[22] |
2035 |
2036 |
Type of cost-based price model
|
Scenario 10 indication-based pricing (IBP)
|
IBP |
IBP |
IBP |